Skip to content
Siliq, Kyntheum(brodalumab)
Kyntheum, Siliq (brodalumab) is an antibody pharmaceutical. Brodalumab was first approved as Siliq on 2017-02-15. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis. It is known to target interleukin-17 receptor A.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Siliq
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Brodalumab
Tradename
Proper name
Company
Number
Date
Products
SiliqbrodalumabValeant Pharmaceuticals Luxembourg S.Ã .r.l.N-761032 RX2017-02-15
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
siliqBiologic Licensing Application2020-06-12
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
psoriasisEFO_0000676D011565L40
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AC: Interleukin inhibitors
— L04AC12: Brodalumab
HCPCS
No data
Clinical
Clinical Trials
48 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PsoriasisD011565EFO_0000676L4032109428
Psoriatic arthritisD015535EFO_0003778L40.5—131—5
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Systemic sclerodermaD012595EFO_0000717M341—1——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hidradenitis suppurativaD017497L73.231———4
Rheumatoid arthritisD001172EFO_0000685M06.913———3
AsthmaD001249EFO_0000270J4512———3
Crohn diseaseD003424EFO_0000384K50—2———2
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atopic dermatitisD003876EFO_0000274L20————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBRODALUMAB
INNbrodalumab
Description
Brodalumab (human mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID1174395-19-7
RxCUI1872251
ChEMBL IDCHEMBL1742996
ChEBI ID—
PubChem CID—
DrugBankDB11776
UNII ID6ZA31Y954Z (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
IL17RA
IL17RA
Organism
Homo sapiens
Gene name
IL17RA
Gene synonyms
IL17R
NCBI Gene ID
23765
Protein name
interleukin-17 receptor A
Protein synonyms
CD217, CDw217, IL-17 receptor A
Uniprot ID
Q96F46
Mouse ortholog
Il17ra (16172)
interleukin-17 receptor A (Q60943)
Variants
Clinical Variant
No data
Financial
Brodalumab - AstraZeneca
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,091 documents
View more details
Safety
Black-box Warning
Black-box warning for: Siliq
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
6,416 adverse events reported
View more details